RNA Therapeutics Expert Joins Kylin's Scientific Advisory Board
WEST LAFAYETTE, Ind.--(BUSINESS WIRE)--Jul 1, 2010 - Officials at Kylin Therapeutics, Inc. announce that RNA interference and genetics expert John J. Rossi, Ph.D., will serve on the company's Scientific Advisory Board.
"John Rossi brings more than 30 years of research and experience in RNA interference (RNAi), molecular biology, genetics and gene therapy to our team," said Eric Davis, president and CEO of Kylin Therapeutics. "His guidance will be extraordinarily beneficial to our Scientific Advisory Board."
Rossi's research focuses on applying RNAi and other gene silencing-based strategies for the treatment of HIV infection and cancer. Kylin has engineered its pRNA nanotechnology to induce gene silencing for the treatment of cancer, HIV and other viral diseases.
Rossi currently serves as dean of the Irell and Manella Graduate School of Biological Sciences, as well as chair and professor of the Department of Molecular and Cellular Biology, at Beckman Research Institute of City of Hope in Duarte, Calif. He completed his postdoctoral fellowship at Brown University. He has authored more than 275 peer-reviewed papers and more than 70 book chapters. In 2002 he received the Merit Award from the Division of AIDS of the National Institute of Allergy and Infectious Diseases.
Other members of Kylin's Scientific Advisory Board include: Homer Pearce, Ph.D., retired vice president of cancer research at Eli Lilly and Co.; Peixiuan Guo, Ph.D., founder and endowed chair and director of the University of Cincinnati Nanomedicine Development Center; Rodney Pearlman, Ph.D., partner at RPM Pharma; David Johnston, Ph.D., vice president and global head of clinical trials at Laboratory Corporation of America; and Olke Uhlenbeck, Ph.D., professor and chair of the department of biochemistry, molecular biology and cell biology at Northwestern University.
About Kylin Therapeutics, Inc.
Kylin Therapeutics, Inc. (http://www.kylintherapeutics.com), is a biotechnology company based in the Purdue Research Park that employs a revolutionary RNA nanoparticle technology platform called "pRNA" to exploit the enormous potential of RNA-based therapeutics for treatment of many common diseases. This visionary platform has enormous potential to combine into one nanoparticle all possible RNA functionalities including receptor antagonism/activation, cell targeting/delivery and gene knockdown through mechanisms like RNA interference. Kylin's goal is to unlock the full potential of RNA for the treatment of disease.
Posted: July 2010